Get the Stockscreener App
2.53
0.00%
0.00
Aerovate Therapeutics Inc stock is traded at $2.53, with a volume of 749.79K.
It is up +0.00% in the last 24 hours and down -4.89% over the past month.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
See More
Previous Close:
$2.53
Open:
$2.53
24h Volume:
749.79K
Relative Volume:
0.99
Market Cap:
$73.14M
Revenue:
-
Net Income/Loss:
$-75.52M
P/E Ratio:
-0.9731
EPS:
-2.6
Net Cash Flow:
$-56.92M
1W Performance:
+0.00%
1M Performance:
-4.89%
6M Performance:
+73.29%
1Y Performance:
-86.43%
1-Day Range:
$2.45
$2.64
1-Week Range:
$2.45
$2.64
52-Week Range:
$1.25
$32.41
Aerovate Therapeutics Inc Stock (AVTE) Company Profile
Name
Aerovate Therapeutics Inc
Sector
Industry
Phone
617-443-2400
Address
930 WINTER STREET, WALTHAM
Compare AVTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTE
Aerovate Therapeutics Inc
|
2.53 | 73.14M | 0 | -75.52M | -56.92M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Aerovate Therapeutics Inc Stock (AVTE) Latest News
STOCKHOLDER ALERT: The M&A Class Action Firm Continues To Investigate MergerAVTE, BCOV, ALVR, AE - cnhinews.com
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Update - Defense World
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Down 5.3% in November - MarketBeat
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc.AVTE - The Eastern Progress Online
Verition Fund Management LLC Sells 149,137 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Pulmonary Arterial Hypertension Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novartis, Insmed Inc, Chugai Pharma, Merck Sharp & Dohme, Janssen Pharma, Aerovate - The Globe and Mail
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, PFIE, EMKR on Behalf of Shareholders - GlobeNewswire Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE an - GuruFocus.com
GSA Capital Partners LLP Has $865,000 Stock Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - MarketBeat
Short Interest in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Declines By 17.3% - MarketBeat
Wedbush Research Analysts Raise Earnings Estimates for AVTE - Defense World
What is Wedbush's Forecast for AVTE FY2024 Earnings? - MarketBeat
Aerovate Therapeutics Reports Q3 Loss Amid Strategic Shift - TipRanks
Finansavisen - Finansavisen
Jade Biosciences’ Merger with Aerovate Therapeutics - Global Legal Chronicle
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATSG, STAF, AVTE on Behalf of Shareholders - Marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Air Transport Services Group, Inc. (Nasdaq– ATSG), Micropac Industries, Inc. (OTC – MPAD), Aerovate Therapeutics, Inc. (Nasdaq – AVTE), Outbrain Inc. (Nasd - ForexTV.com
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc.AVTE - Marketscreener.com
Aerovate Therapeutics Enters into Merger Agreement with Jade Biosciences - Defense World
How Fairmount’s Paragon incubator steered two more companies to NASDAQ - BioCentury
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - Marketscreener.com
Kuehn Law Encourages OB, AVTE, B, and MNTX Investors to Contact Law Firm - The Malaysian Reserve
SEC Form 425 filed by Aerovate Therapeutics Inc. - Quantisnow
Form 425 Aerovate Therapeutics, Filed by: Aerovate Therapeutics, Inc. - StreetInsider.com
Aerovate (AVTE) Shares Rally As Market Responds To A Merger Agreement - Stocks Telegraph
Jade, another biotech spinout of Paragon, to merge with Aerovate - BioPharma Dive
Jade Biosciences and Aerovate announce merger deal - Investing.com
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Aerovate to Merge With Jade Biosciences, Pursue Kidney Treatment - MarketWatch
Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Aerovate climbs on all-stock merger deal with Jade - MSN
Aerovate stock rises on all-stock merger deal (AVTE:NASDAQ) - Seeking Alpha
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement - GlobeNewswire
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Down 21.4% in October - MarketBeat
Aerovate Therapeutics regains Nasdaq compliance - Investing.com India
Aerovate Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Cubist Systematic Strategies LLC Makes New Investment in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Analyzing Aerovate Therapeutics Inc (AVTE) After Recent Trading Activity - Knox Daily
Aerovate Therapeutics announces board member resignation - Investing.com India
Aerovate Therapeutics announces board member resignation By Investing.com - Investing.com UK
Aerovate Therapeutics Board Member Maha Katabi Resigns - TipRanks
XTX Topco Ltd Invests $35,000 in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Aerovate Therapeutics Inc Stock (AVTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aerovate Therapeutics Inc Stock (AVTE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dake Benjamin T | SEE REMARKS |
Aug 01 '24 |
Option Exercise |
1.74 |
1,507 |
2,622 |
14,252 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 17 '24 |
Buy |
1.67 |
928,110 |
1,549,944 |
7,893,678 |
| Eldridge George A | SEE REMARKS |
Jun 14 '24 |
Option Exercise |
2.14 |
15,000 |
32,100 |
20,022 |
| Eldridge George A | SEE REMARKS |
Jun 14 '24 |
Sale |
25.03 |
15,000 |
375,450 |
5,022 |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER |
Jun 14 '24 |
Option Exercise |
14.59 |
10,600 |
154,654 |
10,600 |
| Verwijs Marinus | CHIEF TECHNICAL OFFICER |
Jun 14 '24 |
Sale |
25.00 |
10,600 |
265,000 |
0 |
| Gillies Hunter | CHIEF MEDICAL OFFICER |
Jun 13 '24 |
Option Exercise |
2.14 |
6,000 |
12,840 |
11,602 |
| Gillies Hunter | CHIEF MEDICAL OFFICER |
Jun 13 '24 |
Sale |
24.50 |
6,000 |
147,000 |
5,602 |
| Gillies Hunter | CHIEF MEDICAL OFFICER |
May 17 '24 |
Option Exercise |
2.14 |
4,000 |
8,560 |
9,602 |
| Gillies Hunter | CHIEF MEDICAL OFFICER |
May 17 '24 |
Sale |
21.08 |
4,000 |
84,332 |
5,602 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):